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CD69, one of the earliest specific antigens acquired
during lymphoid activation, acts as a signal-transducing
receptor involved in cellular activation events, includ-
ing proliferation and induction of specific genes. CD69
belongs to a family of receptors that modulate the im-
mune response and whose genes are clustered in the
natural killer (NK) gene complex. The extracellular por-
tion of these receptors represent a subfamily of C-type
lectin-like domains (CTLDs), which are divergent from
true C-type lectins and are referred to as NK-cell do-
mains (NKDs). We have determined the three-dimen-
sional structure of human CD69 NKD in two different
crystal forms. CD69 NKD adopts the canonical CTLD
fold but lacks the features involved in Ca21 and carbo-
hydrate binding by C-type lectins. CD69 NKD dimerizes
noncovalently, both in solution and in crystalline state.
The dimer interface consists of a hydrophobic, loosely
packed core, surrounded by polar interactions, includ-
ing an interdomain b sheet. The intersubunit core shows
certain structural plasticity that may facilitate confor-
mational rearrangements for binding to ligands. The
surface equivalent to the binding site of other members
of the CTLD superfamily reveals a hydrophobic patch
surrounded by conserved charged residues that proba-
bly constitutes the CD69 ligand-binding site.
The C-type lectin-like domain (CTLD)1 is a conserved protein
module that has been found in numerous proteins with a wide
range of functions (1). This fold was initially identified in a
group of C-type (Ca21-dependent) animal lectins (sugar-bind-
ing proteins) that mediate both pathogen recognition and cell-
cell communication by means of protein-carbohydrate interac-
tions (2). Based on amino acid sequence comparisons,
multidomain arrangement, and functional criteria the exten-
sive superfamily of CTLDs has been subdivided in a variety of
groups (3, 4). Among them, those that are predicted to bind
sugars through coordination to a conserved Ca21 ion are also
known as carbohydrate-recognition domains (CRDs). The
structure of several CRDs has been solved, and their binding to
sugars has been thoroughly characterized (1, 5). Increasing
evidence shows, however, that many of the modules that adopt
a CTLD fold lack the Ca21-coordinating residues that mediate
the classical C-type lectin sugar binding properties, suggesting
that they may serve functions other than saccharide recogni-
tion (1).
The CTLD fold is widely represented among proteins that
mediate the innate immune response (6). In particular, a con-
served genomic region known as natural killer (NK) gene clus-
ter (NKC) encodes for a group of receptors with CTLD-contain-
ing sequences that are involved in modulation of NK-cell
activity and natural host defense (6, 7). Most of these proteins
are type II transmembrane receptors, usually expressed as
disulfide-linked homo- or heterodimers. Each subunit com-
prises a single extracellular CTLD, specifically named NK do-
main (NKD), connected by a neck region of variable length to a
single membrane-spanning region and a short intracellular
N-terminal portion (reviewed in Refs. 8 and 9). The cytoplasmic
regions are often involved in signaling by recruitment, through
specific sequence motifs, of kinases and phosphatases. Alter-
natively, some activating receptors, bearing short cytoplasmic
tails devoid of any specific signaling sequence, associate non-
covalently with membrane-anchored signaling molecules (10).
Some receptors encoded in the NKC, such as the CD94/NKG2
heterodimers and the mouse Ly49 family, have proved to bind
molecules of the major histocompatibility complex (MHC) (11,
12), but for many other receptors ligands have not yet been
identified.
CD69, one of the first described members of the NKC family
of receptors (13–15), is present at the cell surface as a disulfide-
linked homodimer, with subunits of 28 and 32 kDa resulting
from the differential glycosylation at a single extracellular
N-linked glycosylation site (see Ref. 16 and reviewed in Ref.
17). Contrary to other NKC gene products, whose expression is
restricted to NK cells, CD69 has been found in the surface of
most hematopoietic lineages (reviewed in Ref. 18). It is one of
the earliest markers induced upon activation in T and B lym-
phocytes, NK cells, macrophages, neutrophils, and eosinophils.
In addition, it is constitutively expressed on monocytes, plate-
lets, Langerhans cells, and a small percentage of resident lym-
phocytes in thymus and secondary lymphoid tissues (19). CD69
is also present on B cell precursors in the bone-marrow, and
recent studies with CD69-deficient mice revealed its modula-
tory role on B cell development and antibody synthesis (20).
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It has been demonstrated that CD69 acts as a signal-trans-
mitting receptor. Its cytoplasmic portion is constitutively phos-
phorylated on serine residues (21, 22). Even when the actual
ligand that triggers this receptor is not known, cross-linking of
CD69 by specific antibodies activates the extracellular signal-
regulated kinase signaling pathway (23) and has been shown to
induce rise in intracellular calcium concentration, synthesis of
different cytokines and/or proliferation (24–28), and target ly-
sis in interleukin-2-activated NK cells (22). In summary, CD69
wide distribution, along with its activating signal-transducing
properties, suggest an important role of this receptor in the
physiology of leukocyte activation.
As a first step toward better understanding the structural
basis for CD69 function, we have undertaken the production
and analysis of soluble constructs of the CD69 extracellular
region. We report here the three-dimensional structure of hu-
man CD69 NKD determined in two crystal forms. We compare
it with other known CTLD structures, specifically those pres-
ent in NKC receptors, describe its dimeric oligomerization, and
suggest a putative ligand-binding site.
EXPERIMENTAL PROCEDURES
Protein Expression, Refolding, and Purification—The complete NKD
of human CD69 (residues 82–199) was amplified from cDNA (14) by
polymerase chain reaction and subcloned into NdeI-BamHI restriction
sites of pET 26b plasmid (Novagen) (29) by double digestion and sub-
sequent ligation. Restriction sites and a TAA termination codon were
added to the insert using the following primers: CD695s, 59GCGCGC-
GCGCATATGGTTTCTTCATGCTCTG; CD693, 59GCGCGCGGATCCT-
TATTTGTAAGGTTTG. Automatic DNA sequencing (ABI PRISM,
PerkinElmer Life Sciences) of the cloned 1insert using T7 promoter
primer rendered the correct sequence.
The resulting plasmid was transformed into Escherichia coli strain
BL21(DE3), and these cells were grown in LB medium at 37 °C until the
A600 reached 0.7 cm
21 and then induced by addition of isopropyl-1-thio-
b-D-galactopyranoside to 0.5 mM. After 4 h, cells were harvested and
resuspended in Tris-HCl, pH 8.0, 0.2 M NaCl, 5 mM EDTA, 5 mM DTT.
They were lysed by adding lysozyme to a final concentration of 1 mg/ml,
and the viscosity was reduced by sonication. The protein was obtained
as insoluble aggregates forming inclusion bodies, which were exten-
sively washed three times in 50 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 1 mM
EDTA, 1 mM DTT, 0.5% (v/v) Triton X-100 and once in 50 mM Tris-HCl,
pH 8.0, 2 M NaCl, 1 M urea, 1 mM EDTA, 1 mM DTT. The protein was
solubilized in 25 mM MES, pH 6.5, 8 M urea, 10 mM EDTA, 1 mM DTT,
and insoluble material was discarded by centrifugation. The CD69 NKD
was refolded by the method of dilution of denaturing conditions follow-
ing a modification of the protocol originally described for MHC class I
molecules (30). Urea-solubilized CD69 NKD was added by slow dilution
to 1 liter of 0.1 M Tris-HCl, pH 8.5, 400 mM L-arginine, 2 mM EDTA, 6.3
mM cysteamine, 3.7 mM cysteamine, 0.1 mM phenylmethylsulfonyl flu-
oride. Repeated pulses were added every 12 h. After 36 h, the refolding
mixture was concentrated under nitrogen to a volume of 5 ml and
purified by gel filtration chromatography in 25 mM Tris-HCl, pH 7.5,
100 mM NaCl, 0.1 mM EDTA on a Superdex 200 column (Amersham
Pharmacia Biotech). In these conditions, CD69 NKD elutes as a non-
covalent dimer, although the peak shows a slight asymmetry, consist-
ent with an equilibrium between the monomeric and dimeric forms.
Correctly sized fractions were further purified by cation exchange chro-
matography using a Mono S column (Amersham Pharmacia Biotech).
Protein was loaded in 25 mM Tris-HCl, pH 7.0 and eluted with a linear
gradient to 500 mM NaCl in the same buffer.
Crystallization and Data Collection—For crystallization, the protein
was buffer-exchanged into 15 mM Hepes, pH 7.2, 50 mM NaCl and
concentrated to 5 mg/ml. Crystals were obtained by mixing aliquots of
the protein solution with an equal volume of the reservoir solution
containing 0.1 M sodium acetate buffer, pH 4.8, 150 mM zinc sulfate or
sodium sulfate, and 15% polyethylene glycol 6000. Two different crystal
forms grew in these conditions. Long and thin prisms of square section,
which belong to the tetragonal system, predominated, whereas larger
irregular crystals, occasionally with a triangular shape and that belong
to the trigonal system, appeared infrequently. The tetragonal crystals
belong to the space group P43212 with unit cell dimensions a 5 b 5 69.6
Å and c 5 118.6 Å and contain one dimer in the asymmetric unit. The
trigonal crystals belong to the space group P3121 with unit cell dimen-
sions a 5 b 5 48.4 Å, c 5 119.9 Å, a 5 b 5 90°, and g 5 120° and contain
a monomer in the asymmetric unit. For cryogenic data collection, crys-
tals were harvested in a modified reservoir solution, transferred to
harvest buffer containing 15% glycerol or ethylene glycol, and flash-
cooled by plunging into liquid propane. The high resolution data sets
used for the structure refinement of both crystal forms were collected at
beam line ID14-3 of the European Synchrotron Radiation Facility in
Grenoble, France, using a MarResearch charge-coupled device, whereas
the initial data set in the tetragonal form used for the structure deter-
mination was collected at beam line ID14–2 using an ADSC Quantum4
charge-coupled device. Data were integrated, scaled, and merged with
the HKL package (31) (see Table I).
Structure Determination and Refinement—The CD69 structure was
determined in the tetragonal crystal form, which became available first.
The structure was solved by molecular replacement using the AMoRe
package (32) with truncated coordinates of the CD94 dimer (33) as the
search model. Structure factors from 15.0 to 5.0 Å were used for the
rotation and translation functions. Model phases were improved and
extended from 5.0 to 2.6 Å by iterative cycles of density modification in
DM (34), which consisted of solvent flattening and 2-fold averaging. The
resulting electron density maps allowed unambiguous building of the
molecule, including extensive portions, like helix a2, not present in the
initial truncated model.
Crystallographic refinement was carried out in CNS (35) using
standard procedures that included a bulk solvent correction and overall
anisotropic scaling. Automatic refinement, employing the maximum
likelihood amplitude target, was alternated with manual rebuilding in
the graphics program O (36) using both averaged and unaveraged
sA-weighted (37) 2Fo 2 Fc, Fo 2 Fc, and omit electron density maps.
Tight noncrystallographic symmetry restrains were initially applied to
all regions except the flexible loops involved in lattice contacts. When
the high resolution data set for this crystal form became available, the
noncrystallographic symmetry restrains were gradually relaxed based
on the behavior of the Rfree. All regions of CD69 NKD are well ordered,
with the exception of the tip of the b2-b29 hairpin, one residue at the N
terminus, and the last two residues at the C terminus, which show poor
density and high B factors. The model contains residues from 83 to 199
for both subunits, and 69 solvent atoms. The present Rcrys is 24.8, and
Rfree is 27.0 for all data (F . 0) between 25.0 and 1.95 Å.
The trigonal crystal form was readily solved using a partially refined
model from the tetragonal crystal form and was similarly refined in
CNS. Electron density maps clearly showed two possible conformations
for residues at the carboxy end of helix a2. Therefore, residues 133 to
136 were modeled in two alternate conformations with half-occupancy.
All residues, including the b2-b29 hairpin, showed in the electron den-
sity maps. The model contains residues from 83 to 199 for both sub-
units, and 115 solvent atoms. The present Rcrys is 22.9%, and Rfree is
24.4% for all data (F.0) between 20.0 and 1.50 Å. Refinement statistics
for both crystal forms are given in Table I.
Structure Analysis—Structure superpositions were done with SHP
(38). Solvent-accessible surface areas were determined with NACCESS
(39) using a probe radius of 1.4 Å and default atom radii (40), and cavity
volumes were determined with SURFNET (41). Calculation of hydrogen
bonds was carried out with HBPLUS (42) using the program’s default
values. Figures were produced with GRASP (43) and BOBSCRIPT (44)
and rendered with RASTER3D (45).
Alignments—The human CD69-NKD sequence was aligned to repre-
sentatives of the NKD family using ClustalW at ExPASy on the Inter-
net and were subsequently edited manually based on the known struc-
tures of rat mannose-binding protein (MBP)-A (PDB accession code
1ytt), mouse Ly49A (1qo3), and human CD94 (1b6e). Sequences were
retrieved from GenBankTM (hCD69, NP_001772.1; hMAFA-L,
AAC32200; hAICL, NP_005118; hLLT1, NP_037401; hNKRP1A,
NP_002249; hKLRF1, AAF37804; hCLEC2, AAF36777.1; hCD94,
NP_002253; hNKG2A, NP_002250.1; mLy49A, I49361) and Swiss-Prot
(mCD69, P37217; rMBP-A, P19999). The alignment figure was drawn
using ESPript (46).
RESULTS AND DISCUSSION
Structure Determination and Quality of the Models—Human
CD69 consists of a 40-residue intracellular domain, a 21-resi-
due transmembrane region, and an extracellular portion that
comprises a 20-residue neck and an NKD of 118 amino acids.
Soluble forms of CD69 NKD, comprising residues 82 to 199,
were prepared by in vitro refolding from material expressed in
E. coli. Recombinant CD69 NKD retains binding to a panel of
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specific monoclonal antibodies recognizing four distinct
epitopes (16), and it behaves as a noncovalent dimer during gel
filtration (results not shown).
The structure of CD69 NKD was determined by molecular
replacement in two different crystal forms, tetragonal and trig-
onal, and refined to 1.95 and 1.50 Å, respectively. The quality
of the diffraction data and refinement statistics are given in
Table I. The tetragonal crystal form contains two molecules in
the asymmetric unit, related by a molecular 2-fold axis. The
electron density is continuous in the final 2Fo 2 Fc map from
residues 83 to 199, except for the exposed b2-b29 hairpin that
shows weak density and appears to be disordered (see below for
a description of secondary structure elements). In the trigonal
crystal, the CD69 NKD dimer is crystallographic, and there is
a single molecule in the asymmetric unit. In this crystal form,
all residues (83 to 199), including the b2-b29 hairpin, are in
good, continuous density in the final electron density maps.
The C-terminal end of helix a2 shows static disorder and has
been modeled in two alternate conformations in the trigonal
form.
Pairwise superpositions of the three independent copies for
CD69 NKD give r.m.s. deviations from 0.27 to 0.40 Å for main
chain atoms between residues 89 and 198. The largest differ-
ences are focused in the domain N terminus, around the b turn
(residues 86–89), which precedes strand b0, and the b2-b29
hairpin. In the tetragonal form, this flexible hairpin is exposed
to the solvent, whereas in the trigonal crystal it is better
ordered because of crystal packing interactions. Description of
the structure is based on the high resolution trigonal model
unless specifically stated.
The CD69 NKD Fold—The a-carbon trace of CD69 NKD is
shown in Fig. 1A. As predicted by its amino acid sequence, the
overall structure of CD69 NKD displays the salient features of
the CTLD fold. The domain, with overall dimensions of 44 3
32 3 30 Å, consists of two connected antiparallel b sheets and
two a helices, like in the CRD of C-type animal lectins (1) and
mouse Ly49A NKD (47) (Fig. 1B). Strand b2 acts as a connec-
tion between the two b sheets formed by strands b0, b1, b5, b2,
and b19 in the lower part of the molecule (following the stand-
ard view for CTLD folds as shown in Fig. 1) and strands b29, b2,
b3, and b4 in the upper part. This portion of the molecule is
also characterized by a long stretch, connecting strands b29 and
b3, lacking regular secondary structure. This region corre-
sponds to the Ca21-binding site of true C-type lectins. The two
helices, a1 and a2, are located one on each side of the extended
b structure.
There are three intrachain disulfide bonds in CD69 NKD
(Fig. 1), two of which (Cys113–Cys194 and Cys173–Cys186) corre-
spond to the characteristic invariant disulfides found in all
CTLDs. The third disulfide bond, Cys85–Cys96, connects a loop
at the N terminus, which precedes the first b strand (b0), with
strand b1 by linking two cysteines separated by 10 residues in
this segment. This disulfide is only found in long-form C-type
lectins (including lithostathine, tetranectin, and factors IX/X-
binding protein) (4) and appears to be present in most NKD
domains (Fig. 2). In members of the rodent Ly49 gene family,
however, these two bonded cysteines are separated by only four
residues and are located on contiguous b strands (47) (Fig. 1B).
Despite the low sequence identity between CD69 NKD and
other CTLDs, which ranges from around 20% with CRDs of
animal lectins to almost 30% for other NKDs, the overall struc-
ture of the domain is highly conserved. Superposition of CD69
with other CTLDs gives rise to r.m.s. deviations of between 1.2
Å for 100 equivalent Ca atoms with Ly49A and 1.4 Å for 95
equivalences with rat MBP (48). The major differences among
them occur at the N terminus, the position of helix a2, hairpin
b2-b29, the loop connecting it to strand b3, and hairpin b3-b4
(Fig. 1B). These regions coincide with segments displaying
higher variability in length and amino acid sequence among
members of the NKD family (Fig. 2). Overall, CD69 NKD is
more similar to long-form CTLDs, like tetranectin or litho-
stathine, and to other NKDs, like Ly49A. Although based on
sequence identity the NKD structure closer to CD69 is that of
the CD94 subunit of the NK-cell receptor CD94/NKG2 (around
28% identical), their superposition gives an r.m.s. deviation of
1.4 Å for 97 equivalent Ca positions. This relatively poorer
match is mostly due to differences between helix a2 in CD69
and the equivalent region in CD94. In the crystal structure of
TABLE I
Data collection and refinement statistics for human CD69
Data collection
Data sets P43212 P43212 P3121
Resolution rangea (Å) 50.0–2.30 50.0–1.95 50.0–1.50
(2.35–2.30) (2.00–1.95) (1.53–1.50)
Measurements 80597 98431 151066
Unique reflections 13929 21836 26542
Completeness (%) 98.7 (98.4) 99.1 (99.2) 98.6 (100.0)
I/s(I) 20.2 (4.0) 27.5 (5.4) 33.5 (15.6)
Rmerge (%) 6.8 (31.1) 6.1 (20.2) 6.2 (10.6)
Refinement
Resolution range 25.0–1.95 20.0–1.50
Rcryst/Rfree 24.8/27.0 22.9/24.4
Reflections
working set 19826 (90.0%) 24561 (91.3%)
test set 2010 (9.1%) 1961 (7.3%)
Number of copies in asymmetric units 2 1
Number of nonhydrogen protein atomsb 1926 956 [54]
Number of solvent atoms 69 115
r.m.s. deviations from ideality
bond length (Å) 0.007 0.009
bond angle (°) 1.41 1.57
bonded B factors (Å2) 2.27 1.82
Ramachandran plotc
most favored (%) 90 92.4
allowed (%) 10 7.6
generously allowed (%) 0 0
disallowed (%) 0 0
a Numbers in parentheses correspond to the highest resolution shell.
b Numbers in brackets represent atoms in dual conformation.
c As calculated by PROCHECK (60).
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the CD94 NKD homodimer, this helix is replaced by a loop that
is involved in the dimerization interface (33). CD94 forms, with
distinct members of the NKG2 family, heterodimers that are
involved in the recognition of the nonclassical MHC class I
molecule HLA-E (49–51). The unraveling of this a helix in the
crystal structure of CD94 NKD could be because of the forma-
tion of the homodimer, whose physiological role is uncertain.
The amino acid sequence at this region retains a distribution of
hydrophobic residues that appears suitable for the formation of
an a helix, but analysis of sequence alignments reveals that, in
CD94 and NKG2 proteins, this segment is two residues shorter
than in the majority of NKD sequences. Whether the lack in
CD94 of this a helix is due to the formation of the homodimer
or consequence of the deletion at the C-terminal end of this
segment would have to await the determination of the struc-
ture of a CD94/NKG2 heterodimer.
CD69 and other NKDs differ substantially from canonical
C-type lectins in that they lack the Ca21-binding site that is
critical for carbohydrate recognition in CRDs. The departure of
the equivalent regions in different NKDs from the canonical
Ca21-binding site appears gradual. In Ly49A, three side chains
are in a position similar to that of Ca21-coordinating residues,
whereas in CD94 two appear in an equivalent position. CD69
shows a deletion of five residues that constitute loops 3 and 4 in
the CRDs (Fig. 1B), both structures involved in Ca21 and
carbohydrate binding, and only one residue (Asp171) is located
FIG. 1. Structure of human CD69 and comparison with other members of the NK-cell receptor family and the CRD of rat MBP. A,
stereoview of the a-carbon trace of CD69 NKD. Every tenth residue is represented as a gray sphere and numbered according to its order in the
full-length protein. Segments are colored based on secondary structure assignments, as calculated with program DSSP (59). The a helices are
shown in red, b strands are shown in blue, and the rest of the residues are shown in yellow. Disulfide bonds are represented by green ball-and-stick
models. The N- and C termini of the domain, which are less than 7 Å apart, are labeled. B, fold of CD69 NKD. Comparison with other members
of the NK-cell receptor family and the CRD of rat MBP-A as a prototype of animal lectins is shown. Ribbon diagrams of the NKDs from human
CD69, human CD94 (PDB entry 1b6e), mouse Ly49A (1qo3), and the CRD of rat MBP-A (1ytt) are shown in a common orientation obtained by
pairwise superpositions. Ca21 ions bound to MBP-A are shown as light blue spheres, whereas its loop regions without regular secondary structure,
three of them involved in Ca21 coordination, are labeled L1 to L4. Secondary structure elements in CD69 have been labeled following the
numbering for MBP-A, prototype of the family. Therefore, the first b strand, which is absent in MBP-A and is characteristic of the long-form
CTLDs, has been labeled as b0, whereas the strand that forms a b-hairpin with strand b2 has been named b29. Differences in the orientation of
helix a2, which is absent in CD94, are evident.
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in a position roughly equivalent to any of the side chains
involved in the coordination of the Ca21 ion in C-type lectins.
Furthermore, this aspartate is not conserved and is replaced by
a glycine in mouse CD69. The extensive alteration of the pu-
tative binding site for carbohydrates in CD69 argues against its
binding to sugars, at least using the same mechanism as C-type
lectins. This is consistent with a recent report showing binding
neither to monosaccharides nor to various polysaccharides but
only a weak binding signal to fucoidan (52).
The CD69 NKD Dimer—CD69, along with other receptors
encoded in the NKC, is a dimeric type II membrane protein.
Most receptors in this group appear to be covalent dimers
through the formation of one or a few interchain disulfide
bridges in the neck, a region that connects the NKD to the
single membrane-spanning segment and presents high varia-
bility among members of the family. The extracellular part of
CD69 encompasses a neck of around 20 amino acids (residues
62–84), which contains the cysteine (Cys68) involved in the
interchain disulfide bridge, and the globular NKD. The recom-
binant CD69 NKD used in this work forms noncovalent dimers
in both crystal forms analyzed. Furthermore, it behaves as a
dimer during size-exclusion chromatography. In the trigonal
crystal, the dimer is crystallographic, whereas in the tetrago-
nal form there are two CD69 copies in the asymmetric unit
related by a molecular 2-fold axis. The two dimers are almost
identical, with an r.m.s. deviation of 0.35 Å for their main chain
atoms. This difference is in the same range as that between the
two independent copies in the asymmetric unit of the tetrago-
nal crystal form (0.4 Å).
The dimer has overall dimensions of 30 3 35 3 70 Å and is
stabilized by both intermolecular hydrogen bonds and hydro-
phobic interactions (Figs. 3 and 4). An intermolecular b sheet
extending through both subunits is formed through antiparal-
lel pairing of their N-terminal b strands (b0). At the ends of the
paired b strands and over them, additional polar interactions
are established. The main-chain carbonyl of Glu87, located in
the b turn preceding chain b0, forms two hydrogen bonds with
main-chain and side-chain nitrogen atoms of Gln83 at the b
turn connecting strands b0 and b1. Asp88, in the same b turn as
Glu87, establishes a salt bridge with Lys127, located at the N
terminus of helix a2. At the domain N terminus, and over the
intermolecular b sheet, Ser84 from both subunits associate with
each other through several hydrogen bonds. Although these
interactions, between Ser84 at the N termini of both subunits,
are seen in the two crystal forms, it cannot be excluded that
they are a consequence of the truncated domain used for these
crystallographic studies. Interestingly, in a group of recently
described receptors expressed on the surface of human macro-
phage and dendritic cells, which appear to have CTLDs with a
functional Ca21-binding site, Ser84 is replaced by a cysteine
residue (53–55). Based on the structure of CD69, where the
side chains of Ser84 are hydrogen bonded through their hy-
droxyl groups, it seems probable that the equivalent cysteine in
those receptors could well be involved in an interchain disulfide
bridge.
Beneath the intersubunit b sheet, the two subunits associate
through the juxtaposition of the C-terminal half of helix a2
(Fig. 4). A hydrophobic core is formed by side chains projecting
FIG. 2. Structure-based sequence alignment of NKDs for CD69, selected NK-cell receptors, and the rat MBP-A CRD. NK-cell
receptors have been arranged in two groups. The first group contains human CD69, its mouse homologue, and other human C-type lectin-like
receptors encoded in the NK complex, which, based on their amino acid sequences, do not appear to use carbohydrates as ligands. The second group
contains the mouse Ly49A receptor, also encoded in the NK complex, whereas the third group includes the prototype animal lectin, rat MBP-A.
Residues strictly conserved are shown by white characters on a red background. They include the four cysteines involved in the two disulfide
bridges conserved in the C-type lectin-like superfamily and the glycine residue where strand b2 switches from one b sheet to another. Residues
well conserved within the first NKD group are depicted by red letters, and the rest are in black. A blue frame denotes similarity across groups. The
secondary structural elements and every tenth residue for CD69 are displayed over the sequences. Helices are represented by red squiggles, and
b strands are represented by blue arrows. The paired numbers (1 to 3) correspond to the bonded cysteines in CD69. Ly49A residues labeled as
orange boxes correspond to those involved in molecular contacts with its ligand, the mouse MHC class I molecule H-2Dd, as observed in the crystal
structure of their complex (47). Rat MBP-A residues enclosed in yellow boxes indicate those whose side chains coordinate the Ca21 ion involved in
carbohydrate binding (48).
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from helix a2 (Phe131, Tyr135) and from the bottom of the
intermolecular b sheet (Val90, Tyr92). The side chain of Arg134,
also on helix a2, extends across the dimer interface and forms
a hydrogen bond with the carbonyl of Tyr135 at the carboxy end
of the same helix on the neighboring subunit; this interaction
probably stabilizes the helix dipole. Underneath the hydropho-
bic core there are contacts between Tyr138, in the loop connect-
ing helix a2 to strand b2, and Asn178 and Thr179, both at the b
turn between strands b3 and b4. The packing at the hydropho-
bic core is loose, and there is an interdomain cavity of 75.5 Å3
between the aromatic side chains of Phe131 and Tyr135 (Fig.
4B). In the high resolution trigonal form, there is static disor-
der at the C terminus of helix a2, and residues 133 to 136 show
two alternate conformations (Fig. 5). This disorder appears to
be triggered by a displacement of the side chain of Tyr135 to fill
the empty cavity at the dimer interface. In one conformation,
Tyr135 fills a cavity formed by residues Val90, Tyr97, Ile99,
Phe131, Ile132, and Ile193 from its own subunit. In the second
conformation, Tyr135, together with the backbone of neighbor-
ing residues, has been displaced to pack against residues
Phe131, Tyr135, and Arg134 of the symmetry-related subunit.
The r.m.s. difference for Tyr135 in the two conformations is 2.8
Å. This alternate conformation cannot occur simultaneously in
both subunits, because it would give rise to steric clashes
around the 2-fold axis. Although these dual conformations are
not observed in the tetragonal crystal, perhaps because of its
more limited resolution, disorder in this region is manifested as
a diffuse electron density and higher thermal factors for the
side chain of Tyr135, which are also consistent with certain
structural variability at the interface. The residues involved in
the formation of this interdomain cavity, especially the two
aromatic side chains, are conserved in other members of this
family (Figs. 2 and 3), suggesting that this feature may also be
present in other receptors. Plasticity at the dimer interface was
also observed in Ly49A when bound to its MHC class I ligand
(Fig. 3). In the complex, the Ly49A subunits are not related by
a strict 2-fold axis, probably because of packing restrictions in
the simultaneous binding to different sites on two MHC mole-
cules (47). There is a shift in the position of the 2-fold axis with
respect to the N-terminal b strand that results in a slightly
different arrangement of the subunits so that juxtaposed a
helices do not run roughly parallel but are approximately
aligned. This departure from dyad symmetry is accompanied
by structural differences between several residues at the
interface.
These packing defects and flexibility at the dimer interface of
NKDs can provide a structural mechanism to allow conforma-
tional rearrangements to facilitate the simultaneous binding of
the two subunits of the dimer to oligomeric or different ligands.
Protein cavities at domain interfaces have been suggested to
facilitate such movements (56). Furthermore, the flexible neck
region would allow various orientations of the NKD domains
with respect to the cell membrane, whereas the intermolecular
disulfide bridge would ensure that subunits would not
dissociate.
The dimer arrangement in CD69 is very similar to that
observed for the CD94 crystallographic dimer, even though
helix a2 has been replaced by a loop in the latter. After super-
position of one subunit of both dimers, the other two can be
superimposed after a rotation of only 6°. In CD69, the total
buried surface area between the subunits is 1673 Å2. Atoms
buried at the interface are 48% nonpolar, and there are twelve
hydrogen bonds and two salt bridges. The CD94 dimer buries a
similar overall surface (1224 Å2), but the percentage of nonpo-
lar atoms involved is higher (61%), and there are only 2 hydro-
gen bonds. Ly49A, partly because of the absence of an N-
terminal loop preceding strand b0, buries a smaller surface
(930 Å), with only 3 hydrogen bonds. The dimer from the
tunicate lectin TC14, an example of a naturally dimeric C-type
lectin, buries 1687 Å2 and forms 10 hydrogen bonds, very
similar values to those of CD69, but the atoms buried at the
interface are more hydrophobic (73%). The formation of dimers
in TC14 also occurs between helix a2 and the N-terminal b
strand. However, the arrangement of the subunits is different,
because it involves much more extensive contacts between the
sides of the helices, which are arranged side by side, and uses
strand b1 instead of b0, because TC14 is a short-form lectin.
Therefore, although the overall arrangement of the subunits in
these dimeric CTLDs is similar, the detailed interactions in-
volved in oligomerization are different among the various re-
ceptors. These differences could affect the structural plasticity
and stability of the dimers.
The Putative Ligand-binding Site—In all NKD structures
known to date, the apposition of the two monomers generates a
relatively flat, continuous surface that is located opposite to the
N and C termini, and that includes the regions equivalent to
the carbohydrate-binding site of CRDs at opposite ends (Figs. 3
and 6). This is one of the most variable regions, both in struc-
FIG. 3. The CD69 dimer and its comparison to other dimeric
CTLDs. Ribbon diagrams showing two views of dimers for CD69,
CD94, Ly49A, and the tunicate lectin TC14 are displayed. In the left
view, the molecular 2-fold axes run along the vertical. The right view is
rotated 90° from the left one around the horizontal axis, so the molec-
ular 2-fold is perpendicular to the plane of the figure. Secondary struc-
ture elements, as defined by the program DSSP (59), are shown in blue
for b strands and in red for a helices. The disulfide bridges are repre-
sented by green ball-and-stick models, and the Ca21 ions in TC14 are
represented as blue spheres. The first three dimers (CD69, CD94, and
Ly49A) are all NKDs encoded in the NK gene cluster. For CD94 and
Ly49A, their left view has been aligned to that of CD69 by superimpos-
ing only the subunit on the right, so differences in dimerization are
shown as different orientations of their left subunits. The dimerization
arrangements in NKDs are very similar but with some significant
differences. The CD94 dimer is the closest to CD69, although the
segment of CD94 corresponding to helix a2 in other CTLDs does not
form a helix in the homodimer. The Ly49A dimer, which was deter-
mined in complex with the mouse MHC class I molecule H-2Dd, does not
follow strict 2-fold symmetry.
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ture and amino acid sequence, in the NKDs (Fig. 2), and this
variability is consistent with this part of the molecule being
involved in selective binding to ligands by receptors bearing
these domains. For Ly49A, this region has indeed been shown
to contain the binding site for its ligand, MHC class I molecules
(47). This same region has been postulated to constitute the
FIG. 6. Surface analysis of the hypothetical ligand-binding site in CD69. A, representation of the solvent-accessible surfaces of the
ligand-binding site in Ly49A (left) and the equivalent region in CD69 (right). Surfaces have been colored based on the nature of the underlying
atoms (carbons and sulfurs in green, polar nitrogens and oxygens in pink, charged nitrogens in dark blue, and charged oxygens in red). For Ly49A,
the footprinting of its ligand, the mouse MHC class I molecule H-2Dd, has been contoured with a black line. In CD69, relevant residues in the
putative ligand-binding site have been labeled. B, overview of the CD69 dimer with the region highlighted in panel A enclosed in a black box.
FIG. 4. The dimerization interface in CD69. A, stereoview of the dimerization interface in CD69. The two subunits of the dimer are shown
as ribbon diagrams in different colors, yellow and green. The backbone of strand b0 and side chains involved in hydrogen bonds or hydrophobic
interactions are represented by ball-and-stick models. Hydrogen bonds are shown as white broken lines. B, cavity and static disorder at the dimer
interface. A close-up of the hydrophobic cluster at the dimer interface is shown. The solvent-accessible surface and the intersubunit cavity, as
calculated with program SURFNET (41), are shown as a semitransparent surface. For the right subunit, the two alternate conformations for Tyr135
side chain and the backbone atoms of surrounding residues are shown in different colors, solid green and semitransparent green. In the green
subunit, strand b0 is shown as a coil instead of an arrow for clarity.
FIG. 5. Electron density map for helix a2. A 1.5-Å resolution electron density map calculated with sA-weighted (37) 2Fo 2 Fc amplitudes and
model phases for residues Asn130 to Gly137 in helix a2 is shown together with the final refined model. Static disorder in the C-terminal half of the
helix, because of rearrangements at the dimer interface, is evident, especially for the side chain of Tyr135. The two alternate conformations modeled
for residues 133 to 136 are shown in cyan and white, respectively.
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ligand-binding site of the CD94/NKG2 heterodimers (33).
Analysis of the amino acid conservations between human
and mouse CD69 that, at the same time, differ significantly
from other CTLDs, specially those of the NKD family, also
pinpoints this region as functionally relevant, supporting the
suggestion that this region is the potential ligand-binding site
(57). In CD69, this surface is characterized by a central hydro-
phobic patch (side chains of Phe175, Met184, and Leu190 and the
aliphatic portions of Glu185 and Lys188) surrounded by polar
side chains, among which acidic residues (Glu140, Asp171,
Glu180, Glu185, and Glu187) predominate (Fig. 6). The topology
and chemical nature of this putative binding region appear
more similar to a protein-protein recognition site than to a
carbohydrate binding surface (5, 58). This observation is con-
sistent with recent data for recombinant CD69 that showed no
binding signals to the various monosaccharides tested (52).
In summary, this work provides the first structural insights
on human CD69 and constitutes a firm basis for future analysis
of the interactions between this receptor and its ligand(s), once
they are identified. The structure reveals that, whereas the
molecule presents the overall characteristics of the CTLD fold,
it completely lacks the structural features responsible for car-
bohydrate binding. Rather, the putative binding site is more
consistent with this receptor having a proteinaceous ligand.
The identification of a buried cavity at the dimer interface and
the conservation of several key residues involved in its forma-
tion suggest the possibility that this feature, which may confer
flexibility at the dimer, could be also present in other receptors
of the family.
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